These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 38686352)

  • 1. The CNIC-polypill (acetylsalicylic acid, atorvastatin, and ramipril), an effective and cost-saving secondary prevention strategy compared with other therapeutic options in patients with ischaemic heart disease.
    Dalmau R; Cordero A; Masana L; Ruiz E; Sicras-Mainar A; González-Juanatey JR
    Eur Heart J Open; 2024 Mar; 4(2):oeae027. PubMed ID: 38686352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic Burden Associated with the Treatment with a Cardiovascular Polypill in Secondary Prevention in Spain: Cost-Effectiveness Results of the NEPTUNO Study.
    Cordero A; Dalmau González-Gallarza R; Masana L; Fuster V; Castellano JM; Ruiz Olivar JE; Zsolt I; Sicras-Mainar A; González Juanatey JR
    Clinicoecon Outcomes Res; 2023; 15():559-571. PubMed ID: 37489131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effectiveness of the CNIC polypill in secondary cardiovascular prevention in the subgroup of patients of the NEPTUNO study using atorvastatin doses of 20 mg].
    González-Juanatey JR; Cordero A; Masana L; Dalmau R
    Arch Cardiol Mex; 2024 Jun; ():. PubMed ID: 38843861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CNIC-Polypill reduces recurrent major cardiovascular events in real-life secondary prevention patients in Spain: The NEPTUNO study.
    González-Juanatey JR; Cordero A; Castellano JM; Masana L; Dalmau R; Ruiz E; Sicras-Mainar A; Fuster V
    Int J Cardiol; 2022 Aug; 361():116-123. PubMed ID: 35569611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of the CNIC-Polypill versus separate monocomponents in cardiovascular secondary prevention in Spain.
    González-Domínguez A; Durán A; Hidalgo-Vega Á; Barrios V
    Rev Clin Esp (Barc); 2023; 223(7):414-422. PubMed ID: 37352973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of the CNIC-Polypill Strategy Compared With Separate Monocomponents in Secondary Prevention of Cardiovascular and Cerebrovascular Disease in Portugal: The MERCURY Study.
    Aguiar C; Araujo F; Rubio-Mercade G; Carcedo D; Paz S; Castellano JM; Fuster V
    J Health Econ Outcomes Res; 2022; 9(2):134-146. PubMed ID: 36475278
    [No Abstract]   [Full Text] [Related]  

  • 7. The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease - expert panel meeting report.
    Grigorian-Shamagian L; Coca A; Morais J; Perez-Martinez P;
    BMC Proc; 2023 Aug; 17(Suppl 8):20. PubMed ID: 37587509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic study of the cardiovascular polypill. Is there any interaction among the monocomponents?
    González-Juanatey JR; Tamargo J; Torres F; Weisser B; Oudovenko N
    Rev Esp Cardiol (Engl Ed); 2021 Jan; 74(1):51-58. PubMed ID: 31983653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical Decision Algorithms for the Use of the Cardiovascular Polypill in Secondary Prevention in Europe.
    Grigorian-Shamagian L; Edel K; Esteve-Pastor MA; Aceña Á; Silva C; Delgado-Silva J; Ntaios G; Demerouti E; Brotons C
    Front Cardiovasc Med; 2021; 8():663361. PubMed ID: 34504874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event: the international VULCANO randomised clinical trial.
    Mostaza JM; Suárez-Fernández C; Cosín-Sales J; Gómez-Huelgas R; Brotons C; Araujo FP; Borrayo G; Ruiz E;
    BMC Cardiovasc Disord; 2022 Dec; 22(1):560. PubMed ID: 36550424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-life effect on the control of risk factors associated with initiation of the cardiovascular polypill created from equipotent drugs.
    Portela-Romero M; Cinza-Sanjurjo S; Conde-Sabarís P; Rodríguez-Mañero M; Mazón-Ramos P; Rey-Aldana D; González-Juanateyc JR
    Rev Clin Esp (Barc); 2022 Mar; 222(3):131-137. PubMed ID: 34674985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reaching blood pressure guideline targets with the CNIC polypill in patients with a previous cardiovascular event in Mexico: a
    Gómez-Álvarez E; Verdejo J; Ocampo S; Ruiz E; Martinez-Rios MA
    Future Cardiol; 2020 Jan; 16(1):53-60. PubMed ID: 31850802
    [No Abstract]   [Full Text] [Related]  

  • 13. The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention.
    Tamargo J; Castellano JM; Fuster V
    Int J Cardiol; 2015 Dec; 201 Suppl 1():S15-22. PubMed ID: 26747390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study.
    Barrios V; Kaskens L; Castellano JM; Cosin-Sales J; Ruiz JE; Zsolt I; Fuster V; Gracia A
    Rev Esp Cardiol (Engl Ed); 2017 Jan; 70(1):42-49. PubMed ID: 27474481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of the cardiovascular polypill 40mg in secondary cardiovascular prevention.
    Marzal D; Rodríguez Padial L; Arnáiz JA; Castro A; Cosín J; Lekuona I; Guijarro C
    Clin Investig Arterioscler; 2018; 30(5):240-247. PubMed ID: 30017176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CNIC-polypill improves atherogenic dyslipidemia markers in patients at high risk or with cardiovascular disease: Results from a real-world setting in Mexico.
    Gómez-Álvarez E; Verdejo J; Ocampo S; Ponte-Negretti CI; Ruíz E; Ríos MM;
    Int J Cardiol Heart Vasc; 2020 Aug; 29():100545. PubMed ID: 32885029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients.
    Ros-Castelló V; Natera-Villalba E; Gómez-López A; Sánchez-Sánchez A; Chico-García JL; García-Madrona S; Vera-Lechuga R; Matute-Lozano C; de Felipe Mimbrera A; Cruz-Culebras A; Alonso-Canovas A; Masjuan J
    Cerebrovasc Dis Extra; 2020; 10(3):166-173. PubMed ID: 33176324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A practical approach to switch from a multiple pill therapeutic strategy to a polypill-based strategy for cardiovascular prevention in patients with hypertension.
    Coca A; Kreutz R; Manolis AJ; Mancia G
    J Hypertens; 2020 Oct; 38(10):1890-1898. PubMed ID: 32890261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A polypill strategy to improve adherence: results from the FOCUS project.
    Castellano JM; Sanz G; Peñalvo JL; Bansilal S; Fernández-Ortiz A; Alvarez L; Guzmán L; Linares JC; García F; D'Aniello F; Arnáiz JA; Varea S; Martínez F; Lorenzatti A; Imaz I; Sánchez-Gómez LM; Roncaglioni MC; Baviera M; Smith SC; Taubert K; Pocock S; Brotons C; Farkouh ME; Fuster V
    J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2071-82. PubMed ID: 25193393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK.
    Becerra V; Gracia A; Desai K; Abogunrin S; Brand S; Chapman R; García Alonso F; Fuster V; Sanz G
    BMJ Open; 2015 May; 5(5):e007111. PubMed ID: 25991449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.